Ibrutinib (Imbruvica®) is indicated in the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
|07/11/2014||18/12/2014||Full Pharmacoeconomic Evaluation Recommended|
|10/04/2015||06/10/2015||Reimbursement Not Recommended|
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with relapsed or refractory MCL has not been demonstrated. Therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.